Duplicate Document
This document appears to be a copy. The original version is:
EFTA Document EFTA01485665Case File
efta-efta01485665DOJ Data Set 10CorrespondenceEFTA Document EFTA01485665
Date
Unknown
Source
DOJ Data Set 10
Reference
efta-efta01485665
Pages
0
Persons
0
Integrity
Loading PDF viewer...
Summary
Ask AI About This Document
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
JEFFREY EPSTEIN
ACCT. -
For the Period 3/I/Il to 3/31/11
close of business of the date of this statement and, except as otherwise agreed in writing, these valuations do not represent the actual terms at which transactions or securities could be bought or sold or
new transactions could be entered into, or the actual terms on which existing transactions or securities could be liquidated as of the date of this statement. We do not warrant their completeness or
accuracy. These valuations are derived from proprietary models based upon well-recognized financial principles and we have, when necessary to calculate the present value of future cash flows, made
reasonable estimates about relevant future market conditions. Valuations based on other models or different assumptions may yield different results. J.P. Morgan expressly disclaims any responsibility
for (1) the accuracy of the models or estimates used In deriving the valuations. (2) any errors or omissions in computing or disseminating the valuations, and (3) any uses to which the valuations are put.
Valuations are provided for information purposes only and are intended solely for your own use. Please refer to the trade confirmation for details of each transaction.
Please review your statement promptly and report any discrepancies immediately to an account officer whose name appears on the contact page of this statement.
This statement is not an official document for income tax reporting purposes.
Deposits in Foreign Branches are not insured by the FDIC or any other Agency of the Federal Government; Amounts in such foreign accounts do not have the benefit of any Domestic
preference applicable to U.S Banks; certain Foreign accounts are considered reportable to the Internal Revenue Service on a Report of Foreign Bank and Financial Account (TD F 90-22.1).
Important Information Regarding Auction Rate Securities (ARS). ARS are debt or preferred securities with an interest or dividend rate reset periodically in an auction. Although there may be daily,
weekly and monthly resets. there is no guarantee that there will be liquidity. If there are not enough bids at an auction to redeem the securities available for sale, the result may be a failed auction. In the
event of a failed auction, there is no assurance that a secondary market will develop or that the security will trade at par or any other price reflected on statements and online.Accordingly, investors
should not rely on pricing information appearing in their statements or online with respect to ARS. Where J.P. Morgan was unable to obtain a price from an outside service for a particular ARS, the price
column on your statement and online will indicate 'Y0.00' which however should not be relied on as the price at which ARS would trade.
Fund manager disclosure information available upon request
If you have an investment account that is managed by an SEC-Registered Investment Advisor, the Private Bank of J.P. Morgan will provide a copy of the advisor's Form ADV II or brochure upon written
request.
You should have received separate confirmations for each securities transaction. All transactions are subject to the terms and conditions stated on the reverse side of such confirmations and are subject
to the constitution, by-laws. customs and interpretations of the marketplace where executed and governed by and construed in accordance with the laws of the State of New York and all applicable
federal laws and regulations. Further information with respect to commissions and other charges related to the execution of transactions, including options transactions, has been included in
confirmations that were previously furnished to you. Upon written request, JPMS will promptly supply you with the latest such Information.
Shareholders of certain JPMorgan Funds are charged a redemption fee equal to 2% of the proceeds if they exchange or redeem shares of such funds within 60 days of purchase, subject to certain
exceptions set forth in the prospectus of the applicable Fund. Please consult your J.P. Morgan representative for a list of the JPMorgan Funds that impose redemption fees.
Bank products and services are offered through JPMCB and its affiliates. Securities are offered by JPMS and, to the extent noted above. cleared through JPMCC.
If a partial call is made with respect to an issue of securities included in your Account we will allocate the call by a method we deem fair and equitable.
You must promptly advise JPMS of material changes in your investment objectives or financial situation. Unless you inform JPMS otherwise, JPMS will consider the information currently in its files to be
complete and accurate.
J.P. Morgan
Page 8 of 9
Confidential Treatment Requested by JPMorgan
Chase
CONFIDENTIAL
JPM-SDNY-00007014
SDNY_GM_00276212
EFTA01485665
Technical Artifacts (1)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
Wire Ref
reflectedRelated Documents (6)
DOJ Data Set 10Financial RecordUnknown
EFTA01682184
186p
OtherUnknown
FEDWIRE PAYMENT DEBIT ADVICE
DOJ EFTA Data Set 10 document EFTA01273102
16p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,500+ persons in the Epstein files. 100% free, ad-free, and independent.
Support This ProjectSupported by 1,550+ people worldwide
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.